Novartis to Acquire Avidity Biosciences for US$12 Billion Novartis will buy Avidity Biosciences for US$12 billion, gaining its RNA-based therapeutic platform and rare-disease programmes.
African Tax Leaders Meet to Discuss Wealthy Taxation The taxation of the wealthy is a key challenge for tax professionals and policymakers…
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK has acquired exclusive rights from Syndivia for an ADC targeting advanc…
AI Tool Analyzes Global Impact of Research Grants A new AI tool, Funding the Frontier (FtF), has been developed to map the impact of resea…
UK Businesses Rely on Brokers for Risk Management UK businesses are more likely to rely on brokers to identify major risks (78.3%) compare…